[1]Louis D N, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary[J]. Neuro Oncol, 2021, 23(8): 1231-1251.
[2]Ostrom Q T, Gittleman H, Truitt G, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011-2015[J]. Neuro Oncol, 2018, 20(suppl_4): iv1-iv86.
[3]Berdasco M, Esteller M. Clinical epigenetics: seizing opportunities for translation[J]. Nat Rev Genet, 2019, 20(2): 109-127.
[4]Bates S E. Epigenetic therapies for cancer[J]. N Engl J Med, 2020, 383(7): 650-663.
[5]Lu Y J, Chan Y T, Tan H Y, et al. Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy[J]. Mol Cancer, 2020, 19(1): 79.
[6]Shi X B, Kachirskaia I, Yamaguchi H, et al. Modulation of p53 function by SET8-mediated methylation at lysine 382[J]. Mol Cell, 2007, 27(4): 636-646.
[7]Takawa M, Cho H S, Hayami S, et al. Histone lysine methyltransferase SETD8 promotes carcinogenesis by deregulating PCNA expression[J]. Cancer Res, 2012, 72(13): 3217-3227.
[8]Veschi V, Liu Z H, Voss T C, et al. Epigenetic siRNA and chemical screens identify SETD8 inhibition as a therapeutic strategy for p53 activation in high-risk neuroblastoma[J]. Cancer Cell, 2017, 31(1): 50-63.
[9]Hanahan D. Hallmarks of cancer: new dimensions[J]. Cancer Discov, 2022, 12(1): 31-46.
[10]Phillips R E, Soshnev A A, Allis C D. Epigenomic reprogramming as a driver of malignant glioma[J]. Cancer Cell, 2020, 38(5): 647-660.
[11]Haag D, Mack N, Benites Goncalves da Silva P, et al. H3.3-K27M drives neural stem cell-specific gliomagenesis in a human iPSC-derived model[J]. Cancer Cell, 2021, 39(3): 407-422.e13.
[12]Katagi H, Louis N, Unruh D, et al. Radiosensitization by histone H3 demethylase inhibition in diffuse intrinsic pontine glioma[J]. Clin Cancer Res, 2019, 25(18): 5572-5583.
[13]Wu S M, Wang W P, Kong X D, et al. Dynamic regulation of the PR-Set7 histone methyltransferase is required for normal cell cycle progression[J]. Genes Dev, 2010, 24(22): 2531-2542.
[14]Jørgensen S, Elvers I, Trelle M B, et al. The histone methyltransferase SET8 is required for S-phase progression[J]. J Cell Biol, 2007, 179(7): 1337-1345.
[15]Strobel H, Baisch T, Fitzel R, et al. Temozolomide and other alkylating agents in glioblastoma therapy[J]. Biomedicines, 2019, 7(3): 69.
[16]Lee S Y. Temozolomide resistance in glioblastoma multiforme[J]. Genes Dis, 2016, 3(3): 198-210.
|